A randomised, multicentre, double blind, placebo controlled trial to evaluate the efficacy and safety of cilostazol in patients with vasospastic angina

Heart

Volumn 100, Issue 19, 2014, Pages 1531-1536

  Shin, Eun Seok ^a   Lee, Jae Hwan ^b   Yoo, Sang Yong ^a   Park, Yongwhi ^c   Hong, Young Joon ^d   Kim, Moo Hyun ^e   Lee, Jong Young ^a   Nam, Chang Wook ^f   Tahk, Seung Jea ^g   Kim, Jeong Su ^h   Jeong, Young Hoon ^c   Lee, Cheol Whan ^a   Shin, Hwa Kyoung ⁱ   Kim, June Hong ^h  

^a University of Ulsan College of Medicine   (South Korea)

^b Chungnam National University College of Medicine   (South Korea)

^c Gyeongsang National University School of Medicine   (South Korea)

^d Chonnam National University Medical School   (South Korea)

^e Dong A University College of Medicine   (South Korea)

^f Dongsan Medical Center   (South Korea)

^g Ajou University Medical CentSuwon   (South Korea)

^h Pusan National University Yangsan Hospital   (South Korea)

ⁱ Pusan National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CILOSTAZOL; PHOSPHODIESTERASE III INHIBITOR; TETRAZOLE DERIVATIVE;

ADULT; ANGINA PECTORIS; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; CORONARY ARTERY SPASM; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MONITORING; FEMALE; HEADACHE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; SOUTH KOREA; THORAX PAIN; TREATMENT OUTCOME;

ADULT; ANGINA PECTORIS; CHEST PAIN; CORONARY VASOSPASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; HEADACHE; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE 3 INHIBITORS; REPUBLIC OF KOREA; SEVERITY OF ILLNESS INDEX; TETRAZOLES; TREATMENT OUTCOME;

EID: 84921668447     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2014-305986     Document Type: Article

References (30)

1. Chahine RA, Feldman RL, Giles TD, et al. Efficacy and safety of amlodipine in vasospastic angina: an interim report of a multicenter, placebo-controlled trial. The Investigators of Study 160. Am Heart J 1989;118:1128-30.
2. Kimura E, Kishida H. Treatment of variant angina with drugs: a survey of 11 cardiology institutes in Japan. Circulation 1981;63:844-8.
3. Nishigaki K, Inoue Y, Yamanouchi Y, et al . Prognostic effects of calcium channel blockers in patients with vasospastic angina - a meta-analysis. Circ J 2010;74:1943-50.
4. Pepine CJ, Feldman RL, Whittle J, et al . Effect of diltiazem in patients with variant angina: a randomized double-blind trial. Am Heart J 1981;101:719-25.
5. Taylor SH. Usefulness of amlodipine for angina pectoris. Am J Cardiol 1994;73:28A-33A.
6. Kimura Y, Tani T, Kanbe T, et al. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 1985;35:1144-9.
7. Dawson DL, Cutler BS, Meissner MH, et al. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998;98:678-86.
8. Tsuchikane E, Fukuhara A, Kobayashi T, et al. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation 1999;100:21-6.
9. Shiraishi Y, Kanmura Y, Itoh T. Effect of cilostazol, a phosphodiesterase type III inhibitor, on histamine-induced increase in [Ca2+]i and force in middle cerebral artery of the rabbit. Br J Pharmacol 1998;123:869-78.
10. Yoo SY, Song SG, Lee JH, et al. Ef ficacy of cilostazol on uncontrolled coronary vasospastic angina: a pilot study. Cardiovasc Ther 2013;31:179-85.
11. Group JCSJW. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2008): digest version. Circ J 2010;74:1745-62.
12. Downie WW, Leatham PA, Rhind VM, et al. Studies with pain rating scales. Ann Rheum Dis 1978;37:378-81.
13. Chahine RA, Feldman RL, Giles TD, et al. Randomized placebo-controlled trial of amlodipine in vasospastic angina. Amlodipine Study 160 Group. J Am Coll Cardiol 1993;21:1365-70.
14. Anderson TJ. Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol 1999;34:631-8.
15. Nakamura K, Ikomi F, Ohhashi T. Cilostazol, an inhibitor of type 3 phosphodiesterase, produces endothelium-independent vasodilation in pressurized rabbit cerebral penetrating arterioles. J Vasc Res 2006;43:86-94.
16. Ota H, Eto M, Kano MR, et al. Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of Sirt1 in human endothelial cells. Arterioscler Thromb Vasc Biol 2008;28:1634-9.
17. Hashimoto A, Miyakoda G, Hirose Y, et al. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis 2006;189:350-7.
18. Watanabe K, Ikeda S, Komatsu J, et al. Effect of cilostazol on vasomotor reactivity in patients with vasospastic angina pectoris. Am J Cardiol 2003;92:21-5.
19. Kawanabe Y, Takahashi M, Jin X, et al. Cilostazol prevents endothelin-induced smooth muscle constriction and proliferation. PLoS ONE 2012;7:e44476.
20. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
21. Kim JS, Lee KS, Kim YI, et al. A randomized crossover comparative study of aspirin, cilostazol and clopidogrel in normal controls: analysis with quantitative bleeding time and platelet aggregation test. J Clin Neurosci 2004;11:600-2.
22. Dinicolantonio JJ, Lavie CJ, Fares H, et al. Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke. Am J Cardiol 2013;112:1230-4.
23. Katakami N, Kim YS, Kawamori R, et al. The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial. Circulation 2010;121:2584-91.
24. Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010;9:959-68.
25. Friedland SN, Eisenberg MJ, Shimony A. Meta-analysis of randomized controlled trials on effect of cilostazol on restenosis rates and outcomes after percutaneous coronary intervention. Am J Cardiol 2012;109:1397-404.
26. Nakao T, Kimura T, Morimoto T, et al. The long-term efficacy of cilostazol in addition to dual antiplatelet therapy after sirolimus-eluting stent implantation for Japanese patients: an analysis of the 3-year follow-up outcomes from the j-Cypher registry. Cardiovasc Interv Ther 2012;27:161-7.
27. Chen KY, Rha SW, Li YJ, et al. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2009;119:3207-14.
28. Birk S, Kruuse C, Petersen KA, et al. The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow. J Cereb Blood Flow Metab 2004;24:1352-8.
29. Evans RW, Kruuse C. Phosphodiesterase-5 inhibitors and migraine. Headache 2004;44:925-6.
30. Iversen HK, Nielsen TH, Garre K, et al. Dose-dependent headache response and dilatation of limb and extracranial arteries after three doses of 5-isosorbide-mononitrate. Eur J Clin Pharmacol 1992;42:31-5.